Gazyva1000 mg/40 ml

Gazyva is a humanized, glycoengineered type II anti-CD20 monoclonal antibody administered by intravenous infusion under the supervision of a physician experienced in the use of anticancer/biologic therapy. Approved (established) indications include:

• Chronic lymphocytic leukemia (CLL), previously untreated (FDA-approved, combination therapy required): Gazyva, in combination with chlorambucil, is indicated for the treatment of adults with previously untreated CLL.
• Follicular lymphoma (FL), previously untreated (FDA-approved, combination therapy required): Gazyva, in combination with chemotherapy followed by Gazyva maintenance in responders, is indicated for the first-line treatment of adults with stage II bulky, III, or IV follicular lymphoma.
• Follicular lymphoma, relapsed/refractory (FDA-approved, combination therapy required): Gazyva, in combination with bendamustine followed by Gazyva maintenance, is indicated for adults with follicular lymphoma who did not respond to, or who progressed during or within 6 months of completion of, a rituximab-containing regimen.

Gazyva is always given as part of a combination or maintenance regimen for these indications; it is not used as standalone first-line therapy without a partner chemotherapy agent. Use outside these approved settings (e.g. other B-cell malignancies) is considered off-label and should only be undertaken by a specialist based on clinical judgment and emerging evidence.

Each single-dose vial contains Obinutuzumab 1000 mg/40 mL (25 mg/mL) as a sterile, preservative-free liquid concentrate for intravenous infusion, along with pharmaceutically accepted excipients (buffering agents, stabilizers, and a surfactant) used in the formulation. Obinutuzumab is manufactured using recombinant DNA technology in mammalian (Chinese hamster ovary) cell culture.

Gazyva is a humanized, glycoengineered, type II anti-CD20 monoclonal antibody (IgG1 subtype) used in the treatment of certain B-cell malignancies. Unlike type I anti-CD20 antibodies, Gazyva is engineered (through modification of its Fc-region glycosylation) to produce enhanced direct cell death and antibody-dependent cellular cytotoxicity, with relatively lower complement-dependent cytotoxicity. Gazyva is supplied as a liquid concentrate that must be diluted and administered as a slow intravenous infusion in a healthcare setting equipped to manage severe infusion reactions.

Gazyva belongs to the therapeutic class of anti-CD20 monoclonal antibodies, a subgroup of targeted biologic antineoplastic (anticancer) and immunosuppressant agents used in B-cell malignancies.

Mechanism

Obinutuzumab binds specifically to the extracellular loop of the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes (both normal and malignant), but not on hematopoietic stem cells, pro-B cells, normal plasma cells, or other normal tissue. Binding of Obinutuzumab to CD20 initiates B-cell lysis through several mechanisms:

• Antibody-dependent cellular cytotoxicity (ADCC), enhanced by glycoengineering of the antibody's Fc region.
• Antibody-dependent cellular phagocytosis (ADCP).
• Direct induction of B-cell apoptosis (programmed cell death).
• A comparatively lower degree of complement-dependent cytotoxicity (CDC) than type I anti-CD20 antibodies.

The overall effect is profound and sustained depletion of circulating and tissue B lymphocytes, including malignant clones, which underlies the therapeutic effect of Obinutuzumab in CLL and follicular lymphoma.

Gazyva is for intravenous infusion only after dilution in 0.9% sodium chloride, prepared and administered by a healthcare professional; it must never be given as an intravenous push or bolus, and must never be self-administered.

• Mandatory premedication before every infusion: a glucocorticoid (for at least the first cycle), an antihistamine, and acetaminophen/paracetamol, to reduce the risk of infusion-related reactions.
• Antihypertensive medications may need to be withheld for 12 hours before, during, and for 1 hour after each infusion, per institutional protocol, due to the risk of hypotension during infusion.
• Tumor lysis syndrome prophylaxis (adequate hydration and, in patients at high risk, anti-hyperuricemic agents) is recommended, particularly for the first dose.
• Patients must be monitored closely during and for an appropriate period after each infusion, with immediate access to resuscitation medications and equipment for management of severe infusion or hypersensitivity reactions.

Formal pharmacokinetic drug-interaction studies are limited because Gazyva is a monoclonal antibody not metabolized through cytochrome P450 enzymes. Clinically significant considerations include:

• Live and live-attenuated vaccines: Should be avoided during Gazyva therapy and until B-cell recovery, due to the risk of inadequate immune response or vaccine-associated infection from profound B-cell depletion.
• Other immunosuppressive or myelosuppressive agents: Concurrent or sequential use with other immunosuppressants (including chemotherapy backbones used in combination) increases the risk of infection, neutropenia, and thrombocytopenia; blood counts should be monitored closely.
• Antihypertensive medications: May need to be temporarily withheld around the time of infusion because of the risk of infusion-related hypotension (see Administration).

The most common adverse reactions reported with Gazyva (occurring in a substantial proportion of patients) include:

• Infusion-related reactions (very common, can be severe - see Precautions and Warnings)
• Neutropenia and thrombocytopenia (common; monitor blood counts)
• Infections, including upper respiratory tract infections
• Cough
• Musculoskeletal disorders (arthralgia, back pain)
• Diarrhea and constipation
• Fatigue and fever

Less common but serious adverse effects include tumor lysis syndrome, hepatitis B reactivation, progressive multifocal leukoencephalopathy, and severe or fatal infusion reactions (see Precautions and Warnings for full detail). Patients should promptly report fever, signs of infection, unusual bleeding or bruising, or any reaction occurring during or shortly after an infusion.

Pregnancy: Gazyva can cross the placenta and cause fetal B-cell depletion; based on its mechanism of action and animal data, Gazyva may cause fetal harm. It should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus, and only after full discussion with the treating physician. Women of reproductive potential should use effective contraception during treatment with Gazyva and for 18 months after the final dose.

Lactation: It is not known whether Gazyva is excreted in human milk, but human IgG antibodies are known to be excreted in breast milk. Because of the potential for serious adverse effects in a breastfed infant, a decision should be made whether to discontinue breastfeeding or discontinue Gazyva, taking into account the importance of treatment to the mother; a physician should be consulted before breastfeeding during or after Gazyva therapy.

Boxed Warnings

• Hepatitis B virus (HBV) reactivation: Gazyva therapy can result in HBV reactivation, in some cases leading to fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before starting Gazyva. Monitor HBV-positive patients during and for several months after therapy, and consult a liver disease specialist regarding monitoring and antiviral therapy.
• Infusion-related reactions: Gazyva can cause severe, life-threatening, and fatal infusion-related reactions, most commonly with the first infusion. Premedication is mandatory (see Administration); interrupt or slow the infusion for reactions and permanently discontinue for severe or life-threatening reactions.

Other Warnings and Precautions

• Progressive multifocal leukoencephalopathy (PML): A rare but serious and potentially fatal brain infection has been reported with Gazyva. Consider PML in any patient presenting with new or worsening neurological symptoms and refer to a neurologist if suspected; discontinue Gazyva if confirmed.
• Tumor lysis syndrome: Can occur, particularly in patients with high tumor burden or high circulating lymphocyte counts. Institute prophylactic hydration and monitoring, and anti-hyperuricemic agents in high-risk patients.
• Neutropenia and thrombocytopenia: Severe and prolonged cytopenias may occur, including late-onset and/or prolonged neutropenia after completion of treatment. Monitor complete blood counts regularly during and after therapy.
• Infections: Gazyva increases susceptibility to serious, including fatal, bacterial, fungal, and new or reactivated viral infections. Do not administer to patients with an active infection; use caution in patients with a history of recurrent or chronic infections.
• Immunization: Avoid live or live-attenuated vaccines during and after Gazyva therapy until B-cell recovery.

There is limited specific clinical experience with Gazyva overdose. In the event of a suspected overdose or accidental over-infusion, the infusion should be interrupted immediately and the patient monitored closely for infusion-related reactions, cytopenias, and infection. There is no specific antidote for Gazyva. Any suspected overdose should be treated as a medical emergency - seek immediate medical attention or contact emergency services/poison control, with supportive care provided as clinically indicated.

Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Do not shake. Keep out of reach of children. Once diluted for infusion, use within the timeframe specified by the treating facility's protocol, stored as directed by the dispensing pharmacy.

Renal impairment: No formal dose adjustment is established; use with appropriate monitoring, as Gazyva has not been extensively studied in severe renal impairment.

Hepatic impairment: No formal dose adjustment is established; Gazyva has not been extensively studied in hepatic impairment, and hepatitis B status must be assessed before use (see Precautions and Warnings).

Elderly: Gazyva has been used extensively in older adults with CLL, in whom no overall differences in safety were noted compared with younger patients, though age-related decline in organ function and higher rates of comorbidity warrant close monitoring for infection and cytopenias.

Pediatric use: See Pediatric Uses.

Duration of Gazyva treatment is indication-specific: in previously untreated CLL, Gazyva is typically given for 6 cycles (28 days each) in combination with chlorambucil. In follicular lymphoma, induction is typically 6-8 cycles in combination with chemotherapy, followed by Gazyva maintenance therapy given every 2 months for up to 2 years (or until disease progression) in patients who respond to induction. The exact duration is determined by the treating oncologist based on response, tolerability, and disease status.

Obinutuzumab is classified as a monoclonal antibody, specifically an anti-CD20 (B-lymphocyte antigen) targeted biologic agent; therapeutically it is grouped as an antineoplastic/immunosuppressant agent used in hematologic malignancies.

Obinutuzumab is a humanized, glycoengineered type II anti-CD20 monoclonal antibody. It binds the CD20 antigen on the surface of B lymphocytes and triggers B-cell death predominantly through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and direct (non-apoptotic) cell death, with comparatively less reliance on complement-dependent cytotoxicity than type I anti-CD20 antibodies. This results in rapid and sustained depletion of both normal and malignant B cells, producing its therapeutic effect in CLL and follicular lymphoma.

The safety and efficacy of Gazyva have not been established in pediatric patients. Gazyva is not approved for use in children or adolescents, and it should not be used in this population outside of a formal clinical trial setting, given the absence of data on dosing, safety, and long-term effects on immune development in this age group.